(Reuters) -Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator’s inspection at a third-party manufacturing site.

The company was seeking approval for its drug odronextamab to treat follicular lymphoma — a type of cancer that begins in the lymph system, a part of the immune system — in patients whose cancer has returned and who have received at least two prior lines of treatment.

The regulator had first declined to approve the therapy in March last year, seeking more data from enrollments in dose-finding and confirmatory portions of trials testing it.

Regeneron said on Friday the latest FDA decision was due to its inspection at contract manufacturer Catalent’s

See Full Page